Drugs / PU-AD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04505358 | Jan 2023 → Dec 2024 | amyotrophic lateral sclerosis | Samus Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PU-AD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04505358 ↗ |
| Route | Oral | “During the 24 week Treatment Period, subjects will be administered 30 mg PU AD or matching placebo qd, orally, on an empty stomach” NCT04505358 ↗ |